Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

about

Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning.

P2860

Q49669785-A421FA7E-CB82-42FE-9937-14229F90098C

P2860

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

Item

http://www.wikidata.org/entity/Q52149946

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@en

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@nl

type

Item

label

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@en

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@nl

prefLabel

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@en

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@nl

P1476

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

@en

P2093

Ina-Christine Rondak

http://www.w3.org/2001/XMLSchema#string

Markus Oechsner

http://www.w3.org/2001/XMLSchema#string

Michael Molls

http://www.w3.org/2001/XMLSchema#string

Mostafa Farzin

http://www.w3.org/2001/XMLSchema#string

Sabrina Astner

http://www.w3.org/2001/XMLSchema#string

P2860

Standardized evaluation of simultaneous integrated boost plans on volumetric modulated arc therapy.

Helical tomotherapy simultaneous integrated boost provides a dosimetric advantage in the treatment of primary intracranial tumors.

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.

Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time.

The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.

Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?

IMRT: a review and preview.

Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.

Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.

P2888

s00066-015-0888-1

P304

945-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00066-015-0888-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26340939

http://www.w3.org/2001/XMLSchema#string

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

about

P2860

P2860

Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698